Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Expected To Expand Between 2025 And 2029?
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size has experienced considerable growth over recent years. It is projected to expand from $2.68 billion in 2024 to $2.89 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.7%. This historical growth can be largely attributed to an expanding pipeline of peptide therapeutics, an increasing global focus on personalized medicine, growing demand fueled by GLP-1 blockbuster drugs, a rising emphasis on sustainable manufacturing practices, and an increase in the approval rates of peptide therapeutics.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $3.84 billion by 2029, expanding at a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this growth during the outlook period include the rising incidence of chronic diseases, increasing demand for targeted biologic treatments, a surging preference for peptide-based therapies, expanding use of high-purity manufacturing, and heightened investment in biotech research and development. Key trends anticipated within the same forecast timeframe involve progress in solid-phase peptide synthesis, breakthroughs in liquid-phase peptide synthesis, the incorporation of hybrid synthesis methods, improvements in purification technologies, and advanced continuous manufacturing processes.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25870&type=smp
Which Drivers Are Impacting The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
The increasing occurrence of diabetes is projected to fuel expansion in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market. Diabetes is defined as a long-term metabolic condition characterized by high blood sugar (glucose) levels, which occurs due to the body’s inadequate insulin production or impaired insulin utilization. The rising incidence of diabetes is largely driven by higher obesity rates, since excessive body fat leads to insulin resistance and interferes with blood sugar regulation. Peptide therapeutics utilize contract API manufacturing to facilitate the mass production of drugs that mimic hormones, thereby improving insulin secretion and glucose management for diabetes. As an illustration, a report released in March 2025 by the Office for Health Improvement and Disparities, a UK-based government department, indicated that the documented prevalence of type 2 diabetes among adults aged 17 and over in England reached 7.0% by March 2024, an increase from 6.8% in March 2023. Consequently, the escalating prevalence of diabetes is spurring the expansion of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market.
What Are The Major Segment Categories Driving The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Growth?
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market covered in this report is segmented –
1) By Scale Of Operation: Preclinical Or Clinical, Commercial
2) By Synthesis Method: Non Chemical Synthesis, Chemical Synthesis
3) By Enterprise Type: Large Enterprise, Small And Medium Enterprises
Subsegments:
1) By Preclinical Or Clinical: Discovery And Preclinical Development, Phase II Or III Manufacturing, Phase I Manufacturing
2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing, Tech Transfer And Scale-up, Lifecycle Management Or Process Optimization
What Are The Major Trends Driving The Growth Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
Leading companies in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market are concentrating on developing innovative solutions, such as the continuous flow synthesis platform, to optimize production and manage the increasing complexity in drug development. This continuous flow synthesis platform integrates multiple stages—reaction, separation, concentration, and crystallization—into a single, uninterrupted process, utilizing real-time in-line measurement to enable high-precision, non-destructive monitoring and efficient scale-up. For instance, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), announced the launch of its good manufacturing practice (GMP)-compliant Naruto Plant, which is equipped with a continuous flow synthesis platform for peptide and nucleotide API production. The platform allows for the rapid and high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, substantially reducing lead times and production costs. This innovation is addressing the growing market demand for advanced peptide-based therapeutics by providing scalable, efficient, and cost-effective API manufacturing solutions.
Who Are The Major Companies Operating In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CEM Corporation, CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., BCN Peptides S.A.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25870&type=smp
Browse Through More Reports Similar to the Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market 2025, By The Business Research Company
Peptide Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Peptide Synthesis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/peptide-synthesis-global-market-report
Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model